PTEN and colorectal carcinoma: It is, therefore, crucial to develop inhibitors of the PI3K/AKT/mTOR pathway with rational targets in mind, such as PTEN loss and PIK3CA-activating mutations, in combination with downstream molecular marker evaluations, which is more likely to yield success than current approaches in CRC treatment.